Advertisement

Topics

Genmab’s Daratumumab Meets Primary Endpoint in Late-Stage Multiple Myeloma Study

16:46 EDT 24 Aug 2017 | Speciality Pharma Journal

Copenhagen, Denmark; August 24, 2017 — Genmab A/S (Nasdaq Copenhagen: GEN) announced today topline results from the Phase III ALCYONE study (MMY3007) of daratumumab in combination with bortezomib, melphalan and prednisone (VMP) versus VMP alone as front line treatment for newly diagnosed patients who are not considered candidates for autologous stem cell transplantation (ASCT). The study met …

Original Article: Genmab’s Daratumumab Meets Primary Endpoint in Late-Stage Multiple Myeloma Study

NEXT ARTICLE

More From BioPortfolio on "Genmab’s Daratumumab Meets Primary Endpoint in Late-Stage Multiple Myeloma Study"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Stem Cells
Track and monitor developments in stem cell research and commercial development.  Follow the tabs above to read the latest global news, research, clinical trials on stem cells and follow companies active in the stem cell industry.  BioPort...

Transplantation
Organ transplantation is the moving of an organ from one body to another or from a donor site to another location on the patient's own body, for the purpose of replacing the recipient's damaged or absent organ. The emerging field of regenerative ...